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ABSTRACT
Objectives: Sarcoma has a predilection to metastasis
to the lungs. Surgical excision of these metastases
(pulmonary metastasectomy) when possible has
become standard practice. We reviewed the published
selection and outcome data.
Design: Systematic review of published reports that
include survival rates or any other outcome data.
Survival data were put in the context of those in a
cancer registry.
Setting: Specialist thoracic surgical centres reporting
the selection and outcome for pulmonary
metastasectomy in 18 follow-up studies published
1991–2010.
Participants: Patients having one or more of 1357
pulmonary metastasectomy operations performed
between 1980 and 2006.
Interventions: All patients had surgical pulmonary
metastasectomy. A first operation was reported in 1196
patients. Of 1357 patients, 43% had subsequent
metastasectomy, some having 10 or more
thoracotomies. Three studies were confined to patients
having repeated pulmonary metastasectomy.
Primary and secondary outcome measures:
Survival data to various time points usually 5 years and
sometimes 3 or 10 years. No symptomatic or quality of
life data were reported.
Results: About 34% and 25% of patients were alive
5 years after a first metastasectomy operation for bone
or soft tissues sarcoma respectively. Better survival
was reported with fewer metastases and longer
intervals between diagnosis and the appearance of
metastases. In the Thames Cancer Registry for 1985–
1994 and 1995–2004 5 year survival rates for all
patients with metastatic sarcoma were 20% and 25%
for bone, and for soft tissue sarcoma 13% and 15%.
Conclusions: The 5 year survival rate among sarcoma
patients who are selected to have pulmonary
metastasectomy is higher than that observed among
unselected registry data for patients with any
metastatic disease at diagnosis. There is no evidence
that survival difference is attributable to
metastasectomy. No data were found on respiratory or
any other symptomatic benefit. Given the certain harm
associated with thoracotomy, often repeated, better
evidence is required.
INTRODUCTION
Pulmonary metastasectomy is a well-
established component in the management
of sarcoma. Metastases may be conﬁned to
the lung where, surrounded by air contain-
ing lung, they are readily detected on radio-
graphs and are usually surgically accessible.
The Cooperative Osteosarcoma Study Group
(COSS) found that, of 202 patients who had
ARTICLE SUMMARY
Article focus
▪ Sarcoma metastases are characteristically blood
borne and predominately in the lungs.
▪ Lung metastases are readily imaged and can be
removed, while sparing lung parenchyma, often
with minimally invasive techniques.
▪ Pulmonary metastasectomy for bone and soft
tissue sarcoma entered clinical practice about
40 years and has become established as a stand-
ard of care.
Key messages
▪ A systematic review of the literature discovered
no randomised trial or any other formal attempt
to compare survival following pulmonary metas-
tasectomy with what might have been the
outcome in similar patients without this surgery.
▪ There is no evidence in the literature of palliative
benefit from pulmonary metastasectomy.
▪ Detrimental effects on breathing place a limit on
repeated and extensive metastasectomy but no
beneficial effects are documented.
Strengths and limitations of this study
▪ The studies retrieved and systematically reviewed
are believed by specialists in sarcoma care to be
representative of clinical practice and their
experience with management of metastatic
sarcoma.
▪ The data retrieved from clinical follow-up studies
and the cancer registry are so different with
respect to which patients are included, and the
data elements available for analysis, that any
comparisons are tenuous.
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metastases at diagnosis, 81% had lung metastases and
62% only lung metastases.1 In an analysis of three
European Osteosarcoma Intergroup (EOI) randomised
controlled trials of chemotherapy, of 564 patients who
had recurrence, 307 (54%) had metastases only in the
lung.2 Osteosarcoma particularly affects the young, who
are better able to withstand surgery and, if they can be
cured by eradicating the disease, or their survival is sub-
stantially lengthened, there are potentially many years of
life expectancy to be restored.
The decision to perform pulmonary metastasectomy is
usually now made by specialist sarcoma teams and is
based on factors such as the interval since primary
surgery, the number and rate of growth of metastases,
and their response to chemotherapy. The surgical
approach may be videothoracoscopic or by thoracotomy,
and surgery may be through staged lateral thoractomies
or bilateral through an anterior approach. The pulmon-
ary resections are also ‘individualised’ depending on the
location, size and number of metastases, with an implicit
commitment to spare as much lung parenchyma as pos-
sible. It may be this degree of variability which makes
data tabulation difﬁcult. The authors of the 2011 EOI
analysis acknowledged that “Amongst the limitations is
the limited information on how the recurrences were
treated. However, all patients were treated in experi-
enced sarcoma centres and it is likely that all patients
received the best available treatment for their recur-
rence. This includes, whenever possible, complete resec-
tion of a local recurrence and/or surgical treatment of
all distant recurrences in case of resectable disease.”2
In 2006, the UK National Institute for Health and
Clinical Excellence (NICE) which issues guidance to the
National Health Service in England and Wales, pub-
lished a manual for commissioners of cancer service on
‘Improving Outcomes for People with Sarcoma’.3 The
manual is more about organisation than guidance on
clinical practice and states that “The management of
chest wall, intrathoracic sarcomas and pulmonary metas-
tases requires a combination of skills available from a
sarcoma multidisciplinary team (MDT) and a thoracic
surgeon, often combined with plastic surgical recon-
structive skills.” Included in this guidance is the advice
on surveillance for the appearance of pulmonary metas-
tases and states in that context “None of the 21 patients
who presented between follow-up visits with symptomatic
pulmonary metastases were considered candidates for
potentially curative surgical resection of their metastases.
Resection of pulmonary metastases was performed for
24 of the 36 patients whose asymptomatic recurrence
was discovered by surveillance chest x-ray or staging CT
scan”3 based on evidence reviewed.4 5 There is evident
readiness to operate on asymptomatic pulmonary metas-
tases in sarcoma patients but evidence for the practice,
or guidance as to which patients are believed to beneﬁt,
cannot be inferred from this practice manual.
Thoracic surgeons are increasingly being asked to
remove lung metastases as part of the overall
management for a wide range of cancers. In a survey
conducted by the European Society of Thoracic
Surgeons (ESTS)6 practice varied considerably. In par-
ticular, there was a wide range of opinions on the weight
to be placed on factors known to be associated with sur-
vival such as the time elapsed since diagnosis of the
primary tumour and the number of metastases seen on
imaging. This survey was part of a wider programme of
work called The European Society of Thoracic Surgeons
Lung Metastasectomy Project.7 In the introduction to
the published report the leaders of the project con-
cluded “the level of evidence to support current practice
is too low to set ﬁrm recommendations to the members
of ESTS.” At the time of writing up The Lung
Metastasectomy Project of the ESTS an up-to-date review
of metastasectomy for sarcoma was not available and the
report went to press without it. We have therefore under-
taken a literature search and a systematic review of pul-
monary metastasectomy for sarcoma.
MATERIAL AND METHODS
Eligibility criteria
A literature search was conducted according to PRISMA
2009 recommendations.8 9 We considered eligible all the
articles in the English language, from 1990 to the ﬁrst
week of June 2011, which contained at least 20 patients
and any data on surgical outcome(s). Reviews and teach-
ing articles which contributed no data for analysis were
excluded. Thames Cancer Registry (TCR) data were
extracted for all cases of bone and soft tissue sarcoma
registered from 1985 to 2008.
Types of participant
All patients of any age undergoing pulmonary metasta-
sectomy from any type of sarcoma (bone, soft tissue and
mixed series) regardless of ﬁrst time or repeated
surgery.
Type of intervention
First time or repeated metastasectomy from sarcoma.
Information sources
A Medline search was conducted using OVIDSP inter-
face. Medline web interface at http://www.pubmed.gov
was also searched. The TCR data was used as the
comparator.
Electronic search
The search expression used was: (lung.mp) AND (metas-
tasectomy.mp) AND (sarcoma.mp).
Study selection
One author (MS) evaluated the reports’ quality from
titles and abstracts identiﬁed from the electronic data-
base searches according to the predeﬁned eligibility cri-
teria. The full text articles of studies that potentially met
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the inclusion criteria were retrieved to assess deﬁnite eli-
gibility for inclusion.
Data collection process
The data were extracted by two of the authors (MS and
FF) independently and then checked by another author
(TT).
Data items
The selected papers were searched and, where available,
data were extracted with respect to:
▸ Research methodology employed.
▸ The purpose of the study.
▸ The patient population from which pulmonary metas-
tasectomy patients were drawn.
▸ Inclusion and exclusion criteria.
▸ Demographic data on patients selected and reported.
▸ The interval between primary surgery and diagnosis
and pulmonary metastasectomy.
▸ Chemotherapy use.
▸ Surgical approach, whether open or videothoraco-
scopic.
▸ Surgical techniques employed.
▸ Survival data.
▸ Statistical analyses of factors related to outcome.
▸ Consideration of second and subsequent metastasect-
omy operations.
▸ Symptoms and respiratory performance.
TCR data were extracted for stage, data on interven-
tions, sex ratio, median age and survival.
RESULTS
The initial search returned 98 articles. In addition, the
reference lists of all papers were searched. We retrieved
a further 17 articles, to make the total up to 115 having
excluded duplicate records by title, authors or DOIs.
Sixty-ﬁve articles were excluded by title and/or abstract
according to the speciﬁed criteria. The full text of the
remaining 50 articles was retrieved. Of these 32 were
excluded because they did not meet the criteria on full
text review or because they duplicated data given in
other included studies.
We retained 18 articles published since 1990 for inclu-
sion in the systematic review: ﬁve report on ﬁrst and
subsequent pulmonary metastasectomy for bone
sarcoma,10–14 six on soft tissue sarcoma15–20 and four on
mixed sarcoma series.21–24 The information in tables 1–4
are extracted from these 15 studies which include data on
the patients’ ﬁrst pulmonary metastasectomy. Three of
the 18 are conﬁned to repeat pulmonary metastasect-
omy.25–27 One of these27 contained 14 patients rather
than the speciﬁed minimum of 20 patients but is a
further report providing outcomes for repeat metastasect-
omy in some of the patients reported from the same insti-
tution and was therefore included.13
With respect to research methodology, there were no
randomised controlled trials. There was one comparison
study in which patients who had undergone videothora-
coscopic resection were matched with patients who
had undergone a thoracotomy approach.24 There were
no protocol-based prospective studies. There was one
retrospective cohort study of data obtained from a
Cancer Centre’s institutional Tumor Registry.11 In other
reports, cases were identiﬁed from databases which were
held, as far as we could determine, at an institutional
level10 12–17 20 23 26 27 or departmental level.18 19 21 24 25
It appears that many of the clinical data were retrieved
by retrospective case note review. A statement in a report
from the M.D. Anderson Cancer Centre (MDACC) is
probably representative of the approach to data collec-
tion: “A prospective surgical database was used to iden-
tify metastasectomy patients and missing clinical data
were supplemented in a retrospective manner.”23
In most studies, the stated purpose of analysis was
to report survival following ﬁrst10–21 23 24 or repeated
pulmonary metastasectomy.22 25–27 In 10 of the
18 reports, statistical analyses were performed to identify
patient and tumour characteristics associated with
improved survival following ﬁrst pulmonary
metastasectomy.11 13 14 16 18 19 21 23 25 26
The population from which the patients having pulmon-
ary metastases were drawn, is given in seven publications
(table 1).10–12 14 15 17 23 As can be seen from the footnotes
to the table, no two denominators are deﬁned in the same
way and none are comprehensive at a community level.
Some authors give an upper age limit (not more than 55,12
4014 or 20 years11) but read in context this appears to be to
match the data set of operated patients rather than a prior
policy. Some series include all sites of primary disease while
others are limited to limbs10 12 or trunk and limbs.11 They
variously include all sarcoma patients,23 or only those with
soft tissue sarcoma (STS).17 The proportion of the denom-
inator population recorded as developing pulmonary
metastases ranges between 18% and 50% while the propor-
tion of those with pulmonary metastases who have an oper-
ation to remove them varied from 5% to 88%. The report
with the largest data set (MDACC23) reported that only 1%
of sarcoma patients have a pulmonary metastasectomy. We
have not found it possible to determine how much of the
variation in the recorded data is attributable to varying
selection in clinical practice, the different biology of
tumours according to histology, tumour site or variation
among patients. A large amount of the variation appears to
depend on how wide the net is cast in capturing the
denominator.
Among these 18 studies of pulmonary metastasectomy
for sarcoma the inclusion criteria are much as those
proposed by Thomford28 that the cancer at the primary
site was eradicated, controlled or amenable to
control;10 12 13 15 17–22 24 26 27 that the metastatic
lung disease was amenable to complete resec-
tion;10 11 13 15 18–21 24 26 27 that there was no metastatic
disease elsewhere;10 12 13 15 17–22 24 26 27 and that the
patient was expected to withstand the loss of lung tissue
necessary to give clearance.10–12 15 17–22 24 26 27 In
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Table 1 Data from reports providing the number of patients from which the study population was derived
Publication Histology
Start
date
End
date
All registered
sarcoma
patients (A)
Patients with
pulmonary
metastases (B)
Pulmonary
metastasectomy as
reported in cited
papers in systematic
review (C)
Proportion of
sarcoma
patients with
pulmonary
metastases
(=B/A) (%)
Proportion of patients
with pulmonary
metastases who have
metastasectomy (data
as in reports) (=C/B) (%)
Proportion of all
sarcoma patients
who have
pulmonary
metastectomy
(=C/A) (%)
Antunes
1999
Bone 1989 1997 198* 31 16
Harting
2006
Bone 1980 2000 272† 137‡ 99 50 72 36
Briccoli
2010
Bone 1985 2005 1197§ 369¶ 323 31 88 27
Buddingh
2009
Bone 1990 2008 197** 88†† 56 45 64 28
Gadd 1993 STS 1983 1990 716‡‡ 135§§ 78 19 58 11
Rehders
2007
STS 1991 2002 678¶¶ 121*** 61 18 50 9
Blackmon
2009
Mixed 1998 2006 15744††† 4355‡‡‡ 234 28 5 1
*Patients operated on for osteogenic sarcomas of the limbs were followed in their centre.
†Patients with osteosarcoma of the trunk or extremities who were younger than 21 years and who had medical records available for review.
‡Developed or presented with radiographically evident pulmonary nodules. These 137 patients formed the initial study cohort.
§Patients with histologically proven HGOS of the extremity 55 years old or younger diagnosed at their Institution.
¶First recurrence with metastases located only in the lung.
**Patients under the age of 40 treated for high-grade OS at the Leiden University Medical Center.
††Patients who had pulmonary metastases either at diagnosis or during follow-up.
‡‡Adult patients with a primary or locally recurrent extremity soft tissue sarcoma admitted to MSKCC.
§§iPatients with pulmonary metastases.
¶¶Patients with STS were treated at the Department of Surgery, University Hospital.
***Pulmonary metastasis of STS occurred during follow-up.
†††Patients with soft tissue and bone sarcoma referred to The University of Texas M.D. Anderson Cancer Center.
‡‡‡Patients diagnosed with sarcomatous pulmonary metastases.
HGOS, high grade osteosarcoma; MSKCC, Memorial Sloan-Kettering Cancer Centre; OS, osteosarcoma; STS, soft tissue sarcoma.
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individual instances authors speciﬁed that there should be
no mediastinal or chest wall involvement;17 absence
of pericardial or pleural effusions;12 that the overall opera-
tive risk was acceptable;26 or that there was no other avail-
able more effective treatment.19 In one report, increased
size on chemotherapy was allowable, but not an increase
in the number of metastases.24 One study with ﬁve sub-
groups gave group-by-group criteria which, read in
context, appeared to be deﬁned after exploration of the
available data to facilitate analysis and reporting.23 Criteria
for inclusion or exclusion in the metastasectomy cohort
were not found in three studies.14 16 25
Data are given in table 2 for the 15 studies which
include data on the ﬁrst pulmonary metastasectomy, for a
total of 1168 patients. The average age of bone sarcoma
patients was 17 years based on 377 patients in four studies
with calculable data,10 12 13 excluding the reports limited
to patients aged <21 years11 or <40 years.14 For soft tissue
sarcoma the average age was 46 based on ﬁve studies
including 277 patients16–20 excluding a study where
median and range were given.15
Male sex was predominant in bone sarcoma (65% of
532 patients) but not in soft tissue sarcoma reports
(50% of 277 patients). These differences in age and sex
preclude meaningful amalgamation of outcome data fol-
lowing pulmonary metastasectomy for bone and soft
tissue sarcoma.
The interval between resection of the primary and
ﬁrst pulmonary metastasectomy was provided in 9/15
reports and was highly variable as can be seen from
table 2. There is a degree of consistency in the median
interval of 1–2 years but half of the authors providing
data, operated on synchronous metastases (5 of 10).
Repeat metastasectomy was performed in 43% of
Table 2 Summary data on 15 papers reporting on series of patient undergoing a first pulmonary metastasectomy operation
for sarcoma
Author
Sarcoma patients
who have
pulmonary
metastasectomy
(N)
Age
mean
(years)
Age
range
(years)
Sex
males
Sex
%
male
Median
interval
between
primary and
metastases
(months)
Range
(months)
Mean
number
of mets
resected Range
Bone
Antunes 1999 31 25 10–54 21 68 22 4–122 3.2 1–8
Harting 2006 99 13.9 ±4.2 67 68 0 in 17% 0–NF 1–>10
Briccoli 2010 323 16 4–55 201 62 NF NF NF
Chen 2008 23 19 6–68 15 65 19 0–108 5.0
Buddingh 2010 56 NF NF 40 71 NF
Soft tissue
Gadd 1993 78 (55)* 17–85 NF 14 1–152 NF NF
Smith 2009 94 49 9–75 47 50 15 0–NF 2.5 1–105
Rehders 2007 61 42 18–47 33 54 21 0–3 5.0 1–48
Garcia Franco 2009 22 41 13–82 10 45 18 5–84
Sardenberg 2010 77 45 NF 37 48 NF 3.5
Chen 2009 23 53 15–86 12 52 NF 0–168
Mixed
Snyder 1991 34 23 NF 20 59 19 <6–>24 11 NF
Blackmon 2009 234 <50* 123 53 Varied NF NF NF
Gossot 2009 60 40 34 57 18 NF NF NF
Garcia franco 2010 52 20 5–74 31 60 20 5–189 NF NF
*Median age.
NF means data were not found.
Table 3 The proportion of patients who have second or
subsequent metastasectomy
Series First N Second N Multiple (%)
Rehders 2007 61 13 21
Antunes 1999 31 8 26
Garcia franco 2010 52 16 31
Garcia Franco 2009 22 7 32
Chen (EJSO) 2009 23 8 35
Smith 2009 94 33 35
Briccoli 2005 267 94 35
Briccoli 2010 323 122 38
Buddingh 2010 56 26 46
Sardenberg 2010 77 37 48
Gossot 2009 60 33 55
Blackmon 2009 234 141 60
Chen (EJCTS) 2008 23 14 61
Snyder 1991 34 28 82
This does not include staged bilateral thoracotomies which are
regarded as a single intervention.
Reports are ranked according to the proportion having second and
subsequent metastasectomy interventions. Sequential-staged
operations (eg, lateral thoracotomies planned with an interval of
1–3 weeks) are considered by the authors as a single episode of
treatment.
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patients based on 14/18 reports in which the data could
be extracted (table 3).
Chemotherapy was frequently used but schedules were
variable both within and between publications. Some
authors stated that preoperative and/or postoperative
chemotherapy was given routinely in all cases10 21 26 27 but
more often the practice varied.11–14 16 18 21 One paper
states “The only constant was that when the disease-free
interval was <2 years with a single lung metastasis, no
chemotherapy was added to surgery” and another that it
was at the discretion of the oncologist.19 One group
used chemotherapy preoperatively only when there were
six or more metastases.17 It was also implicit in the text
of several papers that response to chemotherapy was
part of the clinical evidence used to help select patients
for surgery; non-responding and progressing patients
were less likely to be selected for pulmonary metastasect-
omy and this information is not necessarily explicit in
the report. This statement in the report from the
MDACC is representative of this approach: “Those who
developed metastatic disease early with multiple pul-
monary nodules were treated initially with chemother-
apy to determine the pace of disease progression, if any,
on treatment. Patients responding to chemotherapy,
those with stable disease, and those with slow progres-
sion were referred for resection while those with rapidly
progressive metastatic disease received alternative
chemotherapy treatment.”23
Whether videoscopic or open surgery was used, and if
open through what incision, and the surgical technique
used to resect the metastases, are summarised in table 4
for 12/15 papers including data on ﬁrst metastasectomy
operations.10–13 16–21 24 The remaining 3 of the 15
studies were not explicit with respect to the surgical
approach. In the more common surgery for carcinoma
metastasised to the lung, lymphadenectomy has become
an important consideration.29 In these reports concern-
ing sarcoma patients, hilar nodes were not routinely
Table 4 Surgical approaches and resection techniques in reports of first time pulmonary metastasectomy
Report Surgical approach Surgical technique
Snyder 1991 Thoractomy Enucleation
Bilateral disease-staged thoracotomy, 1–2 weeks interval 16/34
Antunes 1999 Thoracotomy 30/31 Enucleation
Median sternotomy 1/31 Wedge resection
Lobectomy
Harting 2006 Thoracotomy, staged or simultaneous bilateral thoracotomies
Median sternotomy
Briccoli 2010 Thoracotomy Wedge resection
Bilateral thoracotomies Lobectomy
Pneumonectomy
Garcia Franco
2010
Thoracotomy 30/52 Wedge 44/52
Sequential bilateral thoracotomy 7/52 Lobectomy 6/52
VATS 10/52 Exploratory thoracotomies 2/52*
Clamshell 5/52
Chen 2008 Thoracotomy Wedge 22/23
Lobe 1/23
Smith 2009 Wedge 74/94
Lobectomy 17/94
Pneumonectomy 3/94
Resection of other thoracic disease 16/94
Rehders 2007 Thoracotomy 29 (48) Wedge resection 52 (85)
Bilateral thoracotomy, two sessions 10 (16)† Lobectomy 9 (15)
Median sternotomy 22 (36)
Garcia Franco
2009
Thoracotomy 19 Wedge 19
VATS 2 Lobectomy 3
Sternotomy 1
Sardenberg 2010 Thoracotomy Complete resection with 10mm margin
Staged bilateral thoracotomy
Chen (EJSO)
2009
Wedge resection 21/23
Lobectomy 1/23
Pneumonectomy 1/23
Gossott 2009 Thoracotomy 29
VATS 31
In a comparative study of the two approaches
*That is to say no resection of sarcoma was performed in these patients.
†These patients have planned sequential operations about 2 weeks apart and it is regarded as a single intervention as opposed to a repeat
metastasectomy operation.
VATS, video assisted thoracic surgery.
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dissected19 or maybe dissected ‘when necessary’.12
This avoidance of lymphatic resection appears to be
linked to the lower rate of lymphatic spread in sarcoma
compared with other thoracic malignancy in which
further spread from the metastases to mediastinal lymph
nodes is frequent.29
There is a strong evident preference for open surgery
(96% of patients had a thoracotomy of some form)
with considerable emphasis placed by several authors
on the importance of manual palpation of the
lung10–12 16 17 20 22 which cannot be achieved through a
purely videoscopic approach. One study speciﬁcally
addressed the question for whether the less invasive
thoracoscopic approach might be as effective24 and it
was concluded that it might be an option if there are no
more than two metastases but this was not derived from
data analysis presented in the publication. The general
use of thoracotomy, often bilateral and repeated metasta-
sectomy in 43% of patients overall represents a high
treatment burden for patients (tables 3 and 4).
TCR data for sarcoma were studied to provide some
context to the overall survival rates of patients with
sarcoma (ﬁgure 1). The Registry has employed its own
four-level staging system since 1960 and stages around
60% of all solid tumours. The classiﬁcation system uses
information in the patients’ notes to determine if the
disease is local (stage 1), has extension beyond the
organ of origin (stage 2), has regional lymph node
involvement (stage 3) or has metastasised (stage 4).
Survival data by stage for two complete decades
1985–1994 and 1995–2004 for both bone and soft tissue
sarcoma are provided in ﬁgure 1. For patients entered as
stage 4 bone sarcoma (metastatic disease at the time of
registration) in those two decades 5-year survival of 20%
and 25% are recorded for bone sarcoma and 13% and
15% for soft tissue sarcoma.
The Registry does not include full data on treatment
but does provide data on the highest surgery code.
These are presented in an abbreviated form in table 5.
According to the selection criteria set out above, since
the stated ﬁrst criterion for pulmonary metastasectomy
was that a radical operation had been successful at the
primary cancer site, it is among the 8% of bone sarcoma
patients and 21% of soft tissue sarcoma patients that
pulmonary metastasectomy patients would be found.
Summary data of sex distribution and the median age
for patients in two completed decades (1985–1994 and
1995–2004) with bone and STS are in table 6.
Five-year survival data are plotted against publication
date (ﬁgure 2) and the size of the series (ﬁgure 3) for
14 of these 15 studies where the data are given, to allow
for visual inspection of time or case volume. Three-year
and/or 5-year survival for the 15 studies including ﬁrst
(and subsequent) metastasectomy data are plotted in
ﬁgure 4.
Five-year survival data are set out in table 7 sorted by
tumour type from 14 of the 15 studies including ﬁrst
(and subsequent) metastasectomy data. Together these
Figure 1 Thames Cancer Registry data. Kaplan Meier survival plots by stage for decades 1985–1994 (above) and 1995–2004
(below) for bone (left) and soft tissue sarcoma (right). Stage 4 (ie, metastasised at the time of diagnosis/registration) in red.
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provide data on 1196 patients having metastasectomy
from as early as 197616 to as recently as 2008.14 Overall
about a third of patients who have had pulmonary
metastasectomy for bone sarcoma and about a quarter
who have had pulmonary metastasectomy for STS
survive beyond 5 years. TCR ﬁve-year survival data for
two complete decades 1985–1994 and 1995–2004 are
included in the table to provide a reference measure of
survival in all sarcoma patients in the registry who were
classiﬁed as stage 4, that is, sarcoma metastasised at pres-
entation/registration. Direct comparison cannot be
made but it is a reminder that an implicit assumption
that the 5-year survivals of the patients in the pulmonary
metastasectomy series would have approached zero
would be incorrect.
We can reasonably deduce that
1. Five-year survival after pulmonary metastasectomy is
not necessarily attributable to the metastasectomy.
2. Five-year survival does not equate to cure since there
are 5-year survivors with metastatic disease.
Five-year survival from 14 of the 15 studies reporting
ﬁrst (and subsequent) pulmonary metastasectomy
operations. They are grouped by sarcoma type and
then by mid-year of the series to aid visual inspection
for time trends. TCR 5-year survival data for stage 4
patients are provided for two complete decades of data
overlapping the reported series. These TCR patients all
had metastases at presentation but not necessarily lung
or lung only.
Data are not available in the publications concerning
the fate of patients beyond 5 years and there are no nar-
rative accounts of the clinical course of these patients.
However, a number of the authors include, in their nar-
rative, a statement of belief in cure for patients who have
recurred in the lung or that their surgery has curative
intent12 14 16 17 19 24 25 and the phrase ‘potentially cura-
tive resection’ is included in NICE guidance.3 Illustrative
statements from recent publications are these from 2009
and 2010
Given the lack of effective systemic therapies, PM remains
the only potentially curative treatment for STS lung
metastases as long as all known disease can be completely
resected with negative margins.16
We demonstrate that after repeated metastasectomies, a
subset of patients can be cured.14
Other authors explicitly state the improbability of cure
attributable to pulmonary metastasectomy. Antunes
writes “The 5-year survival may reach 50%, although
true cure is extremely rare, the majority of patients even-
tually dying of the disease.”10 And Sardenberg et al state
“It should be emphasised that surgery does not change
the biology of the tumor or the metastatic process, and a
deﬁnitive cure for most patients represents the combin-
ation of host histology, tumor spread, response to
Table 5 Highest Surgery Code of Thames Cancer Registry sarcoma patients 1985–2008
Bone STS
N Percentage N Percentage
Total removal of organ, or operation stated to be radical 145 8 3203 21
Partial or debulking operations on the primary tumour 648 35 4935 32
Lymphadenectomy 2 0.1 171 1
Non-tumour removing surgical treatment 160 9 245 2
Haematological procedure (eg, bone marrow transplant) 2 0.1 19 0.1
Investigative procedure only 298 16 2072 14
Type of surgery not known 11 1 59 0.4
No surgery recorded 581 31 4559 30
1847 100 15263 100
STS, soft tissue sarcoma.
Figure 2 Five-year survival rates plotted against the
publication date.
Table 6 Survival data, sex ratio and median age of
patients in Thames Cancer Registry for two decades
1985–1994 and 1995–2004
Year Cases
M/F
ratio
Median
age
Five-year
survival (%)
Bone
1985–1994 762 1.31 35 20
1995–2004 709 1.35 33 25
Soft tissue
1985–1994 5615 0.98 56 13
1995–2004 6256 0.82 58 15
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systemic therapy, and surgical resection, which together
render the patient free of disease.”19
Several reports include multivariate analysis to seek
factors that might determine a greater or lesser survival
rate. The interval between diagnosis or resection of the
primary cancer and the metastasectomy surgery is
the commonest factor reported as being signiﬁ-
cant11 18 19 21 23 25 26 survival usually being better if the
interval was 12 months or longer. Fewer metastases was
also associated with better survival13 14 18 19 23 25 26 30
most commonly at a number of about three or fewer.
Female sex14 16 was also favourable. Patients in whom
there was substantial necrosis following chemotherapy
survived longer.10 11 14 22
No data were found regarding respiratory function or
symptoms in any of the 18 reports. Where mention was
made of respiratory function in the text, it was related to
the decision to operate. Several authors explained that a
point had been, or might be reached, where respiratory
function or respiratory reserve precluded further metas-
tasectomy. No measurement of this or its consequences
for the patients was provided in any report.
DISCUSSION
A major limitation, when interpreting reports of pul-
monary metastasectomy for sarcoma, is the absence of
control data. It is usual in surgery to rely heavily on
evidence from case series, either in the form of retro-
spective case note reviews or less commonly prospective
cohort studies. When there is a clear temporal and
mechanistic relationship between cause and effect,
and the signal is evident from the noise, observational
studies often provide sufﬁcient evidence.31 The simple
evidence of cause and effect cannot be invoked where
there is a widely variable time course and multimodal
treatments as is the case in protracted, repeated and
multimodal treatment of sarcoma.
Efﬁcacy, effectiveness and cost effectiveness are different
measures of the attributes of a treatment. Pulmonary
metastasectomy has been shown to be efﬁcacious in that
complete macroscopic clearance has been achieved; in
appropriately selected cases, R0 resection of all known pul-
monary metastases can be consistently accomplished.
Whether pulmonary metastasectomy is effective in
prolonging life requires proof that survival has been
extended, by metastasectomy, beyond that which would
have occurred without pulmonary metastasectomy.
Cost-effectiveness requires, in addition to survival, mea-
sures of health gained, measures of health lost due to
death and complications, and for these to be costed in
comparison with any alternatives, including no treatment.
This third measure, estimation of cost-effectiveness is
outside the scope of this review and depends on ﬁrst estab-
lishing effectiveness.
Evaluation of the effectiveness in preventing or postpon-
ing death by pulmonary metastasectomy is the common
objective in these clinical reports. The existing practice is
believed to be effective based on repeated experience
worldwide for over 40 years. In 1971, thoracic surgeons at
Memorial Sloane-Kettering reported on 22 patients with
treated osteogenic sarcoma in whom they performed lung
resections.32 The meticulous case by case communication
of that experience merits revisiting (ﬁgure 5).
In the discussion that followed Beattie modestly states:
We reported these data with some reluctance, since they
really constitute a progress report on a clinical research
project underway at Memorial Hospital. We used osteo-
genic sarcomas because they are such serious tumors.
There are occasional spontaneous regressions and good
results; but you saw in the ﬁgures Dr Martini showed that
with amputation we have had a 17% ﬁve-year cure rate.
Of the 83% of patients who died, 5% lived 3 years. Very
occasionally a patient would go on longer before dying.32
Twenty years later33 Beattie reported further
Twenty-year follow-up reveals that at least four of the six
survivors at 10 years survived more than 19 years; one was
lost to follow-up. The patient who died of metastatic
osteogenic sarcoma more than 19 years after her ﬁrst
thoracotomy had a total of nine thoracotomies.
An implicit assumption is embedded in many subse-
quent reports that none of these patients would have
lived beyond 5 years without metastasectomy. There are
Figure 4 Three-year and 5-year survival rates from
publications in table 6 (bone sarcoma red, soft tissue sarcoma
green and mixed series blue).
Figure 3 Five-year survival rates plotted against the size of
the series.
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other reasons, apart from having had pulmonary metas-
tasectomy, for patients with pulmonary metastatic
disease to be alive at and beyond 5 years. These patients
are carefully selected and although it is not possible to
put a reliable ﬁgure on it, they are a minority of all
patients with the disease (table 1).2 It is appropriate to
select patients for surgery and yet comments such as
“survival of (surgically treated) patients was signiﬁcantly
better than of patients ineligible for metastasectomy,
p<0.00001”14 is not an appropriate or meaningful
statistical comparison: the difference is evident but how
much is due to the selection and how much to the
surgery, cannot be determined.
The identiﬁable factors for the selection of suitable
patients include fewer metastases and a longer interval
between the diagnosis and treatment of the primary
and the resection of pulmonary metastases.34 35 Others
which appear in some analyses are tumour doubling time
and the size of the nodule(s) which under surveillance is
a proxy for rate of growth. These are prognostic features
for survival under any circumstance. We also know from
the TCR data that there are 20–25% of patients with
osteosarcoma and about 15% with soft tissues sarcoma,
with metastases at the time of registration, who are alive
beyond 5 years (tables 6 and 7). The narrative accounts
record that there are some natural long-term survivors:
“one patient not operated on remains alive 18 years after
not having surgery.”14 “Long-term survivors appear to
belong to a subset of patients with indolent, lung-only
disease.”36 These natural survivors, who are likely to have
slower progression, and fewer metastases, are likely to be
disproportionately frequent among patients selected
for metastasectomy37 for the selection process is not
random as illustrated in ﬁgure 6. More than 30 years ago
Aberg ﬁrst proposed that selection might be the major
factor determining survival after pulmonary metastasect-
omy38 and returned to this question in 1997.39 It is of
note that none of the authors cite Aberg. It is known that
‘citation distortions create unfounded authority’40 which
has been conﬁrmed in the context of metastasectomy by
a citation network analysis.41
In fact, the effect of selection may easily be underesti-
mated. Multivariable analysis cannot detect more than a
limited number of factors in these relatively small series.
All of these factors may exhibit covariance and they are
all indices of the relative aggressiveness of a cancer.
Failure for one or more of these factors to reach signiﬁ-
cance in any particular Cox model does not refute the
overall ﬁnding. Furthermore, if the knowledge of previ-
ous ﬁnding leads to the exclusion of some patients, the
range of that variable is reduced and it is less likely to be
found in subsequent analyses.42
In this group of young and therefore physically resili-
ent patients there seems to be a strong desire to never
say no, and to push the boundaries for selection for
metastasectomy. It is well established that patients with
more metastases are unlikely to live long after metasta-
sectomy. Nevertheless, there is no apparent upper limit
in many of the reports nor was there for 85% of sur-
geons in the ESTS survey.6 Among the reports of pul-
monary metastasectomy in the present systematic review
some surgeons report very high numbers of metastases
resected. For example “The authors have removed as
many as 80–100 nodules during a single thoracotomy”22
Table 7 Five-year survival and Thames Cancer Registry (TCR) summary data
Author
Sarcoma patients who have
pulmonary metastasectomy (N)
Five-year survival
where provided (%)
Middle date of metastasectomy
series and date ranges for TCR
Bone
Harting 2006 93 23 1991
Briccoli 2010 323 37 1996
Chen (EJCTS) 2008 23 31 1999
Buddingh 2010 56 38 2000
TCR 20 1985–1994
TCR 25 1995–2004
Soft tissue
Gadd 1993 78 18 1987
Smith 2009 94 18 1989
Rehders 2007 61 25 1997
Sardenberg 2010 77 35 1999
Chen (EJSO) 2009 23 44 1999
Garcia Franco 2009 22 23 2002
TCR 13 1985–1994
TCR 15 1995–2004
Mixed
Snyder 1991 34 49 1984
Garcia franco 2010 52 31 2002
Blackmon 2009 234 26 2003
Gossot 2009 60 34 2004
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and in the COSS report “The highest number of pul-
monary nodules surgically removed was 250”’1 are out of
line with the observational evidence that above a count
of relatively few metastases, outcomes are too poor to
justify this surgery. Maybe these high numbers reﬂect
the observation that the preoperative count of nodules
underestimates the true extent of the disease “It is
interesting that despite the presence of only three or
four nodules on many CT scans, up to 50 or more
nodules were found and removed in a number of
these patients.”22 The issue of the relative reliability of
modern imaging versus surgeons’ palpation of the
lung has been considered elsewhere with varying
conclusions.43 44
The extent of necrosis caused by chemotherapy
evident in the excised nodule was found to be a favour-
able feature for survival.10 The clinical response or
failure to respond to chemotherapy was given as factor
in selection in several series. Both of these observations
are evidence that chemotherapy is having an effective in
these patients and has had a demonstrable effect on
their disease. Why then should a survival difference be
attributed to the surgery?
There is a ﬁrm belief that if sarcoma recurs in the
lungs, and the patient is still within the criteria for resec-
tion, further resections should be performed. “The
authors concluded that patients persistently free of the
primary osteosarcoma who developed recurrent resect-
able metastatic disease of the lung should be considered
for reoperation a second, third, or fourth time, as these
patients had similar DFI curves after ﬁve years.”26 This
belief is supported by what might be inappropriate data
interpretation. Consider these statements for example:
“Prognostic factors for increased survival included 3 or
Figure 5 The full display of essential features of the patients and their survival from primary resection to metastasectomy and
subsequently. From Martini et al.32
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greater redo pulmonary operations’;23 “patients with
complete resection for recurrent pulmonary metastasis
show a signiﬁcantly better prognosis after repeat pul-
monary metastasectomy”27 and “repeat metastasectomy
for recurrent pulmonary metastasis also provided a favor-
able overall survival (p<0.041).”20 To undergo a second
metastasectomy a patient has to have survived, and been
without evidence of disease for a reasonable length of
time, to meet the criteria for each subsequent operation.
The problem is exempliﬁed by Sardenberg and collea-
gues. Survival was measured from the ﬁrst thoracotomy
for pulmonary metastasectomy (conﬁrmed with the ﬁrst
author) and was 15, 45 and 48 months, in 35 patients
having only one surgical episode, 24 who had 3 and 13
who had three. The authors provide a statistical analysis
(p=0.077) of the association between more thoracoto-
mies and longer survival. They neglect the fact in their
interpretation that survival after surgery, and for a reason-
able period of time, was a requirement to move to the
next analytical group.19 This way of presenting the data
maximises survivor bias: ongoing survival is an entry cri-
terion to having a further metastasectomy operation.
We found no data, or even a narrative account, con-
cerning the effect of surgery on symptoms. The patients
who are regarded as candidates for metastasectomy are
generally detected on surveillance and presentation with
symptoms probably distinguishes patients as being not
suitable for metastasectomy, either because it represents
extrapulmonary disease or the pulmonary disease is too
advanced. The evidence cited in NICE guidance3 is as
follows: “Detection on the basis of symptoms occurred in
21 patients. Fifteen of these patients presented between
scheduled visits. Seven patients were symptomatic pri-
marily on the basis of their metastatic pulmonary
disease. These patients had diffuse metastatic disease in
all cases, with documented synchronous recurrence
outside the lung, and none was resectable.”5 What is
implicit in many of the reports reviewed is that ultim-
ately they call a halt to repeated thoractomies because
the patient respiratory function will not withstand
further surgery and loss of lung tissue.
Two publications45 46 which appeared in 2011 after
completion of our review and data analysis, and follow-
ing submission, have been brought to our attention by
reviewers. They come from prominent North American
institutions and appeared in a specialist thoracic surgical
journal, The Annals of Thoracic Surgery. The report from
Brigham and Women’s Hospital, Boston, Massachusetts
states in its title “Repeated and aggressive pulmonary
resections for leiomyoma metastases extends survival.”
The report is of 82 patients with a variety of bone and
soft tissues sarcomas between 1989 and 2004. Repeat
metastasectomy was performed in 28/82 with some
patients having three, four or ﬁve thoracic operations.
Operated patients with leiomyosarcoma (31/82) had a
median survival of 70 months compared with 24 months
for other sarcoma subtypes. No control data for survival
among comparable patients, not operated upon, are
Figure 6 A conservative estimate of natural 5-year survivors is set at 5% (15/300 in this depiction) and they are in green.
Ranking patients on the Y and X axes from least to most favourable based on fewer metastases and longer interval since
diagnosis might have the effect of clustering these natural survivors as shown. If selection for surgery is also based on these
factors, it might be the selection rather than the surgery which is associated with a higher than anticipated survival rate shown
here as 10/25 or 40%.
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provided. The text conﬁrms that the surgery was
repeated and aggressive but that survival was extended
as a result cannot be inferred from the data presented
for the reasons given already.
The other report, from the Massachusetts General
Hospital, is of 97 patients with 13 sarcoma subtypes oper-
ated on for pulmonary metastases between 2002 and
2008.46 They report that of 69% of 29 patients who had
multiple operations were alive at 5 years compared with
41% of 60 patients who had a single operation and ﬁnd
the difference to be statistically signiﬁcant and the
bottom line of the conclusions reads “Repeated pulmon-
ary metastasectomy in select patients may improve sur-
vival despite recurrent disease.” But patients have ﬁrst to
be survivors to be candidates for surgery, a point the
authors themselves make in their discussion “Patients in
whom disease rapidly recurred after surgery (either as a
local recurrence or disseminated disease) were probably
selected out from repeated surgical resection.”46 Patients
who thus meet the criteria for a second operation must
necessarily live longer making the argument circular
and the statistical test spurious.
Neither of these papers provides evidence on symp-
tomatic beneﬁt for these patients.
While there are some long-term survivors among
those who have this surgery, the absence of control data
leaves Aberg’s challenge38 39 unrefuted. His hypothesis
was that patients destined to survive longer are more
likely to be selected for surgery and it is the process of
selection, rather than the effect of pulmonary metasta-
sectomy, which is responsible for any survival difference
perceived. Although it would of course be challenging
to perform, a randomised controlled trial is now neces-
sary if we are to see the signal from the noise in this
area of clinical practice.
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